

DATE: July 18, 2025
TO: AHCCCS Providers
AHCCCS Fee-For-Service
AHCCCS Division of Managed Care
AHCCCS MCO Contractors
AHCCCS Office of the Director
FROM: Suzi Berman, AHCCCS Pharmacy Director
SUBJECT: Biosimilars

The purpose of this memo is to provide notice on the biosimilar drug changes that will become effective on August 1, 2025. These changes were announced at the May AHCCCS Pharmacy & Therapeutics Committee Meeting and were also posted on the AHCCCS website under the Pharmacy & Therapeutics Committee section under Pharmacy.

AHCCCS MCO Contractors and the AHCCCS FFS Program will begin to transition members from the brand name medication to the AHCCCS FDA approved preferred biosimilar on August 1st.

For claims that are dispensed by a retail pharmacy, the brand name medication will be rejected at the pharmacy with messaging to use the biosimilar. When a biosimilar is approved by the FDA as interchangeable with the brand name product, the pharmacist can make this prescription change without contacting the prescribing clinician.

When the preferred biosimilar medication does not have the interchangeable designation by the FDA, the pharmacist will have to contact the prescribing clinician for approval to dispense the preferred biosimilar.

For medical claims, the HCPCS codes for the brand name agents and non-preferred biosimilars will be closed by end-of-business day on September 30th and will no longer be covered effective October 1, 2025.

Attached for your perusal is a table of the preferred and non-preferred biosimilar product changes that will be effective beginning August 1, 2025. The table provides the following:

- Brand name product and generic name
- Preferred biosimilar brand name
- Preferred biosimilar chemical name
- Preferred biosimilar manufacturer
- Preferred biosimilar HCPCS Codes
- Preferred products and biosimilars moving to non-preferred
- Brand name and non-preferred biosimilar product HCPCS codes closing on September 30, 2025

As new biosimilars become available, the agency will evaluate them in accordance with the AHCCCS Medical Policy Manual Policy 310-V Prescription Medications, to determine if the agency will be covering the biosimilar or continue to cover the brand name agent.

If you have additional questions, please do not hesitate to contact me at
Suzanne.Berman@azahcccs.gov

AHCCCS BIOSIMILAR UPDATE

Effective Date for Changes: August 1, 2025

Brand Name Product	Generic Name	<i>Preferred Biosimilar Label Name</i>	Preferred Biosimilar Chemical Name	<i>Preferred Biosimilar HCPCS Code(s)</i>	Preferred Biosimilar Manufacturer	Preferred Products Moving to Non-Preferred Status	Non-Preferred Products HCPCS Code(s)
Eylea	Aflibercept	<i>Pavblu</i>	Aflibercept-ayyh	<i>Q5147</i>	Amgen	Eylea Opuviz Yesafili Ahzantive Enzeevu	J0178 Q5153 Unclassified Q5150 Q5149
Humira	Adalimumab	<i>Unbranded Hadlima</i>	Adalimumab-fjkg Adalimumab-bwwd	<i>Q5140 Unclassified</i>	Biocon Biologics Organon	Simlandi Adalimumab-abdm and all other Humira and biosimilar products	Q5140-45 Q5131 Q5103 Q5111 J0139
Avastin (for chemotherapy use only)	Bevacizumab	<i>MVASI Zirabev</i>	No Changes	<i>Q5107 Q5118</i>	Amgen Pfizer	Alymsys Vegzelma Avzivi Avastin	Q5126 Q5129 unclassified J9035
Soliris	Eculizumab	<i>Epysqli</i>	Eculizumab-aagh	<i>Q5151</i>	Teva	Soliris Bkemv	J1299 Q5152
Neupogen	Filgrastim	<i>Releuko Nivestym</i>	Filgrastim-ayow Filgrastim-aafi	<i>Q5125 Q5110</i>	Amneal Pfizer	Neupogen Nypozi Zarxio Granix	J1442 Q5148 Q5101
Neulasta	Pegfilgrastim	<i>Fulphila Fylnetra</i>	Pegfilgrastim-jmdb Pegfilgrastim-pbbk	<i>Q5108 Q5130</i>	Mylan Amneal	Neulasta Udenyca Ziextenzo Nyvepria Stimufend	J2506 Q5111 Q5120 Q5122 Q5127
Lucentis	Ranibizumab	<i>Cimerli</i>	Ranibizumab-eqrn	<i>Q5128</i>	Sandoz	Lucentis Byooviz	J2778 Q5124
Rituxan	Rituximab	<i>Riabni Ruxience</i>	Rituximab-arrx Rituximab-pvvr	<i>Q5123 Q5119</i>	Amgen Pfizer	Truxima	Q5115
Actemra	Tocilizumab	<i>Tyenne</i>	Tocilizumab-aazg	<i>Q5135</i>	Fresenius	Actemra Tofidence	J3262 Q5133
Herceptin	Trastuzumab	<i>Ogivri</i>	Trastuzumab-dkst	<i>Q5114</i>	Mylan-Biocon Biologics	Herceptin Kanjinti Hercessi Herzuma Ontruzant Trazimera	J9355 Q5117 Q5146 Q5113 Q5112 Q5116
Stelara	Ustekinumab	<i>Yesintek</i>	Ustekinumab-kfce	<i>Q5100</i>	Biocon Biologics	Stelara Otulfi Pyzchiva Selarsdi Steqeyma Wezlana Imuldosa	Q5100 Q9999 Q9996-7 Q9998 Q5099 Q5137-8 Q5098